2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - Great Hall BC
Technology and Procedures, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Multi-Systemic Interactions, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Adult, Pediatric
PAPER

382 Multi-omic analysis identifies CT45A as a novel prognostic marker defining two immunologically distinct subsets of hox-dysregulated AML

Salma Abdelbaky, PhD, Anjali Byappanahalli, BS2, Deedra Nicolet, MS3, Kyoko Yamaguchi, BSc4, Yue-Zhong Wu5, Erin Jeremy, MS6, Itallia Pacentine, PhD, MSc7, Lianbo Yu, PhD8, Marina Konopleva, MD, PhD9, Geoffrey L. Uy, MD10, Wendy Stock, MD11, Bethany Mundy-Bosse, PhD12, James Stewart Blachly, MD13, Theodore Paul Braun, MD PhD14, Maria Velegraki, MD, PhD15, Zihai Li, MD, PhD16, Ann-Kathrin Eisfeld, MD17, Kevin R. Coombes, PhD18, Christopher C Oakes, PhD19
1 The Ohio State University, Columbus, Ohio, United States
2 The Ohio State University, Columbus, Ohio, United States
3 The Ohio State University, Columbus, Ohio, United States
4 The Ohio State University, Columbus, Ohio, United States
5 The Ohio State University, Columbus, Ohio, United States
6 The Ohio State University, Columbus, Ohio, United States
7 Oregon Health & Science University, Portland, United States
8 The Ohio State University, Columbus, Ohio, United States
9 Albert Einstein College of Medicine, Bronx, United States
10 Washington University in St. Louis, St. Louis, United States
11 University of Chicago, Chicago, United States
12 The Ohio State University, Columbus, Ohio, United States
13 The Ohio State University, Columbus, Ohio, United States
14 Oregon Health & Science University, Portland, United States
15 The Ohio State University, Columbus, Ohio, United States
16 The Ohio State University, Columbus, Ohio, United States
17 The Ohio State University, Columbus, Ohio, United States
18 Augusta University, Augusta, United States
19 The Ohio State University, Columbus, Ohio, United States

Acute myeloid leukemia (AML) is a heterogeneous malignancy with poor survival. While immune reconstitution after stem cell transplantation remains the main curative approach, targeted immunotherapy has so far been limited by a lack of selective target antigens and incomplete understanding of the AML tumor microenvironment. Varied treatment responses within defined risk categories highlight the need for a better understanding of the complexity of AML.

Using a multi-omics approach integrating clinical, genetic, cytogenetic, transcriptomic, and novel epigenetic markers in a cohort of 294 well-annotated NPM1-mutated (NPM1mut) AML patients, we identified a novel signature defined by expression of the X-linked cancer/testis antigen family 45A (CT45A). CT45A expression stratified NPM1mut patients into two distinct subsets. A subset of other HOX-dysregulated AML, including KMT2A-rearranged (KMT2A-r) patients, also expressed CT45A. Analysis of samples from the Beat AML cohort revealed that CT45A-expressing patients displayed significantly longer overall survival in multivariate analysis (P<0.001), independent of sex, age, blast count, and common mutations including FLT3-ITD, TET2, DNMT3A, and IDH1/2. CT45A-expressing patients showed global and CT45A promoter DNA hypomethylation independent of sex, a more mature phenotype, and enrichment of DNMT3A mutations, while non-expressing patients were enriched for TET2 and IDH1/2 mutations. Transcriptionally, CT45A-expressing patients showed enrichment for HOXA cluster expression and higher MYC pathway activity, suggesting a HOX-MYC co-transcriptional program driving CT45A expression.

We next performed longitudinal single-cell analysis on 24 NPM1mut samples at diagnosis, remission and relapse, accompanied by XVSeq to identify malignant cells. CT45A expression was restricted entirely to malignant cells, with no expression detected in normal hematopoietic and immune cells, and expression levels remained consistent between diagnosis and relapse. We identified a CT45A-positive signature marked by upregulation of leukemic stem cell markers (CD96, CD93, CD37) and MYC-associated/cell-communication genes (ICAMs, ITGAL), validated in independent single-cell studies and bulk cohorts (Beat AML, Leucegene) spanning both NPM1mut and KMT2A-r patients. The CT45A-expressing group displayed divergent immune-evasion mechanisms between subtypes: NPM1mut showed upregulation of immunosuppressive galectins LGALS9 and LGALS3BP, with a trend toward upregulation of non-classical MHC-I molecules at the protein level, while KMT2A-r cases showed consistent MHC-II downregulation. Despite this mechanistic divergence, both subtypes converge on a shared reduced immune surveillance phenotype in CT45A-positive patients. Indeed, publicly available CRISPR screen data using the CT45A-expressing K562 line revealed that CT45A knock out was among the top 10 hits for MHC-I upregulation in response to IFNγ, suggesting CT45A actively contributes to immune evasion with downstream manifestation differing by genetic subtype.

Further investigation of the immune landscape revealed enrichment of naive CD8 T cells in CT45A-expressing patients across cohorts, indicating CT45A is associated with a less activated/exhausted immune landscape. Spectral flow analysis of 29 NPM1mut patients confirmed significantly fewer TIGIT+CD39+ CD4 and CD8 T cells in CT45A-expressing patients. Notably, higher CT45A1 expression was associated with improved response to anti-PD-1 treatment in melanoma (P=0.037), raising the possibility that CT45A could serve as a candidate biomarker for immunotherapy response.

In conclusion, we have identified CT45A as a novel, independent prognostic marker defining two biologically and clinically distinct entities within HOX-dysregulated AML. We propose that CT45A functions as an immunogenic "fire alarm" sensing global epigenetic dysregulation and inciting immune surveillance. Favorable survival in CT45A-expressing patients possibly reflects a primarily immune evasion versus exhaustion immunophenotype, yielding a more functionally intact immune system. Beyond its predictive value, the restriction of CT45A to malignant cells with stable expression through relapse suggests CT45A may represent a novel immunotherapy target in AML.
Anjali Byappanahalli, BS: No relevant conflicts of interest to declare.